WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Eran Broshy Biography and Net Worth

Director of Certara

Eran Broshy is an accomplished, strategically focused board director and private equity operating executive working broadly across the healthcare space, with a demonstrated 35+ year track record of building high-growth public and private healthcare businesses. He served for over a decade as the chief executive officer and chairman of inVentiv Health, Inc. (now part of Syneos), and previously was a management consultant with The Boston Consulting Group and the partner responsible for BCG’s healthcare practice across the Americas.

Mr. Broshy has served on multiple private and public healthcare company boards, and he currently serves on the board of directors of Theravance Biopharma and of Thirty Madison. He is also a member of the Corporation of the Massachusetts Institute of Technology (MIT’s governing body), as chairman of the American Friends of the Open University of Israel, and on the board of governors of the American Jewish Committee.

Mr. Broshy holds an M.B.A. from Harvard University, an M.S. in civil engineering from Stanford University, and a B.S. in civil engineering from the Massachusetts Institute of Technology.

What is Eran Broshy's net worth?: The estimated net worth of Eran Broshy is at least $102,312.63 as of August 21st, 2023. Mr. Broshy owns 9,553 shares of Certara stock worth more than $102,313 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Broshy may own. Learn More about Eran Broshy's net worth.
How do I contact Eran Broshy?: The corporate mailing address for Mr. Broshy and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on Eran Broshy's contact information.
Has Eran Broshy been buying or selling shares of Certara?: Eran Broshy has not been actively trading shares of Certara during the last ninety days. Most recently, on Monday, August 21st, Eran Broshy bought 193 shares of Certara stock. The stock was acquired at an average cost of $16.10 per share, with a total value of $3,107.30. Following the completion of the transaction, the director now directly owns 9,553 shares of the company's stock, valued at $153,803.30. Learn More on Eran Broshy's trading history.
Who are Certara's active insiders?: Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.
Are insiders buying or selling shares of Certara?: During the last year, insiders at the sold shares 6 times. They sold a total of 86,060 shares worth more than $1,151,075.18. The most recent insider tranaction occured on October, 7th when insider Patrick F Smith sold 5,409 shares worth more than $59,661.27. Insiders at Certara own 2.4% of the company. Learn More about insider trades at Certara.
Information on this page was last updated on 10/7/2024.

Eran Broshy Insider Trading History at Certara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/21/2023	Buy	193	$16.10	$3,107.30	9,553

Eran Broshy Buying and Selling Activity at Certara

Certara Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $10.71

$10.51

$11.05

50 Day Range

MA: $10.81

$9.55

$11.71

2 Week Range

Now: $10.71

$9.41

$19.87

Volume

3,240,121 shs

Average Volume

852,739 shs

Market Capitalization

$1.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.